Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture between Croma-Pharma and Gore Range Capital, is the company behind the innovative Saypha® ChIQ™ and Saypha® MagIQ™ injectable hyaluronic acid gels, which are set to launch in the U.S. under the Obagi Medical brand.
This transaction marks a key milestone in Croma-Pharma's international growth strategy and reinforces its commitment to providing scientifically validated, high-quality products for the global aesthetic market.
"We are thrilled to see Novaestiq join forces with Waldencast, a move that amplifies our shared commitment to advancing aesthetic medicine," said Andreas Prinz, CEO of Croma-Pharma GmbH. "The introduction of Saypha® ChIQ™and MagIQ™ to the U.S. market under the Obagi Medical brand marks a significant step in delivering innovative, science-driven aesthetic solutions to patients worldwide."
Saypha®, developed and manufactured by Croma-Pharma, is a globally recognized line of hyaluronic acid (HA) injectables known for their safety, efficacy, and high patient satisfaction. With over 40 years of experience in HA products, Croma-Pharma has produced more than 110 million syringes to date, and its fillers are approved in over 80 markets worldwide. The company maintains a dedicated focus on aesthetic medicine and offers a broad portfolio of minimally invasive treatments.
The upcoming U.S. launch of Saypha® injectables, currently undergoing the FDA approval process,1 is supported by a robust clinical program, including pivotal studies that exceed industry standards in size and diversity. These trials reflect Obagi Medical's and Croma-Pharma's shared commitment to inclusivity and scientific excellence in aesthetic care.
"This partnership is a testament to the strength of our innovation pipeline and our ability to collaborate with visionary partners," added Prinz. "We are confident that Waldencast and Obagi Medical will successfully bring Saypha® to a new generation of U.S. physicians and patients."
Contact
Valentin Gruber
Valentin.gruber@croma.at